Company intelligence / Profile preview

GliaCure, Inc.

Boston, Massachusetts, United Statesbiospace.com ↗

Ownership: Private
Development stage: Phase 1

Overview

GliaCure completed Phase 1a and Phase 1b clinical trials for its lead compound GC021109 in Alzheimer's disease. The Phase 1a trial tested single ascending doses in healthy volunteers to determine safety, tolerability, and pharmacokinetics. The Phase 1b trial tested multiple ascending doses in 39 patients with mild to moderate Alzheimer's disease over 28 days, including biomarker assessments. Both trials were completed by October 2015, but no further information on results has been published.

Therapeutic areas: Neurology
Modalities: Small molecule drug
Industry: Biotech

Drug pipeline

1 asset

GC021109

Beyond the preview

Go deeper on GliaCure, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GliaCure, Inc..

Explore the full profile